Ultragenyx Pharma (RARE), GeneTx Report Investigational New Drug Application Active for GTX-102 in Patients with Angelman Syndrome

Go back to Ultragenyx Pharma (RARE), GeneTx Report Investigational New Drug Application Active for GTX-102 in Patients with Angelman Syndrome
ULTRAGENYX PHARM (NASDAQ: RARE) Delayed: 29.03 +1.59 (5.79%)
Previous Close $27.44    52 Week High $117.12 
Open $27.56    52 Week Low $46.52 
Day High $29.35    P/E N/A 
Day Low $27.49    EPS $-1.97 
Volume 2,067,255